
EquitySector - HealthcareVery High Risk
Regular
NAV (11-Sep-26)
Returns (Since Inception)
Fund Size
₹768 Cr
Expense Ratio
2.42%
ISIN
INF174KA1PW4
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
11 Dec 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+26.06%
+16.11% (Cat Avg.)
Since Inception
+21.77%
— (Cat Avg.)
| Equity | ₹765.23 Cr | 99.68% |
| Others | ₹2.47 Cr | 0.32% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹107.18 Cr | 13.96% |
| Divi's Laboratories Ltd | Equity | ₹71 Cr | 9.25% |
| Torrent Pharmaceuticals Ltd | Equity | ₹36.48 Cr | 4.75% |
| Molbio Diagnostics Ltd | Equity | ₹34.76 Cr | 4.53% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹33.35 Cr | 4.34% |
| Acutaas Chemicals Ltd | Equity | ₹30.03 Cr | 3.91% |
| Cipla Ltd | Equity | ₹28.18 Cr | 3.67% |
| Park Medi World Ltd | Equity | ₹25.79 Cr | 3.36% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹24.95 Cr | 3.25% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹24.92 Cr | 3.25% |
| Gland Pharma Ltd | Equity | ₹23.38 Cr | 3.04% |
| Sai Life Sciences Ltd | Equity | ₹23.36 Cr | 3.04% |
| Fortis Healthcare Ltd | Equity | ₹22.67 Cr | 2.95% |
| Mankind Pharma Ltd | Equity | ₹21.77 Cr | 2.84% |
| Marksans Pharma Ltd | Equity | ₹19.3 Cr | 2.51% |
| Laurus Labs Ltd | Equity | ₹19.15 Cr | 2.49% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹18.89 Cr | 2.46% |
| Rubicon Research Ltd | Equity | ₹18.2 Cr | 2.37% |
| Anthem Biosciences Ltd | Equity | ₹17.86 Cr | 2.33% |
| Ajanta Pharma Ltd | Equity | ₹16.21 Cr | 2.11% |
| Viyash Scientific Ltd | Equity | ₹15.42 Cr | 2.01% |
| Triparty Repo | Cash - Repurchase Agreement | ₹13.6 Cr | 1.77% |
| Orchid Pharma Ltd | Equity | ₹12.62 Cr | 1.64% |
| Corona Remedies Ltd | Equity | ₹12.3 Cr | 1.60% |
| Emcure Pharmaceuticals Ltd | Equity | ₹12.06 Cr | 1.57% |
| Aurobindo Pharma Ltd | Equity | ₹12.02 Cr | 1.57% |
| Jubilant Ingrevia Ltd Ordinary Shares | Equity | ₹11.47 Cr | 1.49% |
| Net Current Assets/(Liabilities) | Cash | ₹-11.13 Cr | 1.45% |
| Rainbow Childrens Medicare Ltd | Equity | ₹9.9 Cr | 1.29% |
| Pfizer Ltd | Equity | ₹8.9 Cr | 1.16% |
| Jubilant Pharmova Ltd | Equity | ₹8.84 Cr | 1.15% |
| Lupin Ltd | Equity | ₹8.75 Cr | 1.14% |
| Metropolis Healthcare Ltd | Equity | ₹8.74 Cr | 1.14% |
| Zydus Lifesciences Ltd | Equity | ₹8.71 Cr | 1.13% |
| Dr. Lal PathLabs Ltd | Equity | ₹8.51 Cr | 1.11% |
| Innova Captab Ltd | Equity | ₹8.3 Cr | 1.08% |
| Laxmi Dental Ltd | Equity | ₹1.27 Cr | 0.17% |
Large Cap Stocks
34.88%
Mid Cap Stocks
20.91%
Small Cap Stocks
39.37%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹723.73 Cr | 94.27% |
| Basic Materials | ₹41.5 Cr | 5.41% |
Standard Deviation
This fund
--
Cat. avg.
16.08%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.63
Higher the better

Since December 2023
Since March 2024
ISIN INF174KA1PW4 | Expense Ratio 2.42% | Exit Load No Charges | Fund Size ₹768 Cr | Age 2 years 9 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹6,37,968 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments